Back to results
US 2015/0306156 A1Published application
Probiotic recolonisation therapy
AssigneeCrestovo LLC
InventorThomas Julius BORODY
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeCrestovo LLC
InventorThomas Julius BORODY
Estimating the term…
The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
1-182. (canceled)
A pharmaceutical composition comprising a plurality of viable non-pathogenic or attenuated pathogenic Clostridia spores, wherein said pharmaceutical composition does not comprise one or more microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, Escherichia coli, Gemmiger, Desulfomonas, Peptostreptococcus, Bifidobacterium, and Monilia.
The pharmaceutical composition of claim 0, wherein said pharmaceutical composition comprises viable Collinsella.
The pharmaceutical composition of claim 0, wherein said pharmaceutical composition comprises viable Bacteroides.
The pharmaceutical composition of claim 0, wherein said pharmaceutical composition comprises viable Escherichia coli.
The pharmaceutical composition of claim 0, wherein said pharmaceutical composition comprises viable Peptostreptococcus.
The pharmaceutical composition of claim 0, wherein said pharmaceutical composition comprises viable Lactobacilli.
The pharmaceutical composition of claim 0, wherein said pharmaceutical composition comprises viable Bifidobacteria.
The pharmaceutical composition of claim 0, wherein said pharmaceutical composition comprises viable Monilia.
The pharmaceutical composition of claim 0, wherein said viable non-pathogenic or attenuated pathogenic Clostridia spores are from one or more species selected from the group consisting of Clostridium absonum, Clostridium argentinense, Clostridium baratii, Clostridium botulinum, Clostridium cadaveris, Clostridium carnis, Clostridium celatum, Clostridium chauvoei, Clostridium clostridioforme, Clostridium cochlearium, Clostridium fallax, Clostridium felsineum, Clostridium ghonii, Clostridium glycolicum, Clostridium haemolyticum, Clostridium hastiforme, Clostridium histolyticum, Clostridium indolis, Clostridium irregulare, Clostridium limosum, Clostridium malenominatum, Clostridium novyi, Clostridium oroticum, Clostridium paraputrificum, Clostridium perfringens, Clostridium piliforme, Clostridium putrefaciens, Clostridium putrificum, Clostridium sardiniense, Clostridium sartagoforme, Clostridium scindens, Clostridium septicum, Clostridium sordellii, Clostridium sphenoides, Clostridium spiroforme, Clostridium sporogenes, Clostridium subterminale, Clostridium symbiosum, Clostridium tertium, Clostridium tetani, Clostridium welchii, and Clostridium villosum.
The pharmaceutical composition of claim 0, wherein said viable non-pathogenic or attenuated pathogenic Clostridia spores are from species selected from the group consisting of Clostridium bifermentans, Clostridium innocuum, and Clostridium butyricum.
The pharmaceutical composition of claim 0, wherein said pharmaceutical composition comprises between about 103 and about 1013 viable cells.
The pharmaceutical composition of claim 0, wherein said pharmaceutical composition comprises between about 105 and about 1011 viable cells.
The pharmaceutical composition of claim 0, wherein said pharmaceutical composition comprises between about 109 and about 1011 viable cells.
The pharmaceutical composition of claim 0, wherein said pharmaceutical composition comprises about 1010 viable cells.
A pharmaceutical composition comprising a plurality of viable non-pathogenic or attenuated pathogenic Clostridia spores, wherein said pharmaceutical composition does not comprise one or more viable microorganisms selected from the group consisting of Bacteroides fragilis ss. Vulgatus, Collinsella aerofaciens, Bacteroides fragilis ss. Thetaiotaomicron, Peptostreptococcus productus II, Parabacteroides distasonis Fusobacterium prausnitzii, Coprococcus eutactus, Collinsella aerofaciens III, Peptostreptococcus productus I, Ruminococcus bromii, Bifidobacterium adolescentis, Gemmiger formicilis, Bifidobacterium longum, Eubacterium siraeum, Ruminococcus torques, Eubacterium rectale, Eubacterium eligens, Bacteroides eggerthii, Clostridium leptum, Bacteroides fragilis ss. A, Eubacterium biforme, Bifidobacterium infantis, Eubacterium rectale III-F, Coprococcus comes, Pseudoflavonifractor capillosus, Ruminococcus albus, Dorea formicigenerans, Eubacterium hallii, Eubacterium ventriosum I, Fusobacterium russi, Ruminococcus obeum, Eubacterium rectale, Clostridium ramosum, Lactobacillus leichmannii, Ruminococcus callidus, Butyrivibrio crossotus, Acidaminococcus fermentans, Eubacterium ventriosum, Bacteroides fragilis ss. fragilis, Bacteroides AR, Coprococcus catus, Aerostipes hadrus, Eubacterium cylindroides, Eubacterium ruminantium, Eubacterium CH-1, Staphylococcus epidermidis, Peptostreptococcus BL, Eubacterium limosum, Tissirella praeacuta, Bacteroides L, Fusobacterium mortiferum I, Fusobacterium naviforme, Clostridium innocuum, Clostridium ramosum, Propionibacterium acnes, Ruminococcus flavefaciens, Ruminococcus AT, Peptococcus AU-1, Bacteroides fragilis ss. ovatus, -ss. d, -ss. f;
A method for treating autism or a Clostridium difficile infection in subject in need thereof, said method comprising administering to said subject an amount of the pharmaceutical composition of claim 0 effective for treating autism or said Clostridium difficile infection.
The method of claim 0, wherein said Clostridium difficile infection is a recurrent Clostridium difficile infection.
The method of claim 0, wherein no existing enteric microflora is removed from said mammalian host prior to administration of said pharmaceutical composition.
The method of claim 0, wherein said subject is pretreated with an antibiotic prior to administration of said pharmaceutical composition, wherein said antibiotic is selected from the group consisting of vancomycin, rifampicin, nitroimidazole, and chloramphenicol.
The method of claim 0, wherein said pharmaceutical composition is formulated as an enteric coated capsule, an enteric coated microcapsule, a powder suitable for reconstitution, a naso-duodenal infusion, or for delivery in the form of an enema or a colonoscopic infusion.
Dependencies are inferred from the claim text.